US EditionPublished • loading... • Updated
Medicus Submits Phase 2 Study Design for Teverelix to FDA
Summary by MyChesCo
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Medicus Submits Phase 2 Study Design for Teverelix to FDA
PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) recently submitted an updated Phase 2 clinical study design to the U.S. Food and Drug Administration for Teverelix, an investigational treatment aimed at preventing recurrent acute urinary retention in men with benign prostatic hyperplasia. The submission is part of the company’s existing Investigational New Drug application and reflects revisions intended to refine study endpoints and reduce…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
